Introduction
============

Inflammatory bowel disease (IBD), including both Crohn's disease (CD) and ulcerative colitis (UC), is characterized by the chronic and remittent-relapsing inflammation of the intestinal tract. IBD affects millions of people worldwide ([@B15]; [@B24]). Although its etiology remains debated, IBD likely results from a combination of environmental, genetic and immunoregulatory factors ([@B13]). Bloody diarrhea, abdominal discomfort, fever, and weight loss are the most common symptoms of patients with IBD ([@B34]; [@B4]). Currently, the treatment of IBD primarily consists of 5-aminosalicylic acid (5-ASA) agents, steroids, antimicrobials, and select immunomodulators ([@B2]). However, these drugs have limitations, and many patients cannot achieve remission. The exploration of novel therapeutic methods is urgently needed. For exploring novel therapeutic methods of IBD, various studies have focused on the potential value of herbal extract, such as *Scutellariae radix*, *Aloysia triphylla*, *Harpagophytum procumbens* and *Chamomile*, and found that the herbal extracts have therapeutic effect in experimental model of IBD ([@B8]; [@B21]; [@B28]; [@B22]).

Recently, the hygiene hypothesis proposed that epidemiological investigations and experimental data have shown that less exposure to parasite infections during early childhood increases susceptibility to immune disorders such as IBD ([@B29]; [@B32]). Studies have demonstrated that helminth products protect against autoimmunity via the innate Type 2 cytokines IL-5 and IL-33 ([@B12]). Furthermore, *Schistosoma mansoni* and *Ancylostoma caninum* soluble proteins hold therapeutic potential to treat 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice ([@B35]). *A. caninum* excretory/secretory products can ameliorate the pathogenesis of colitis in mice ([@B38]), and *Schistosoma japonicum* and *S. mansoni* eggs have modulatory effects on colitis in mice ([@B45]; [@B42]; [@B17]). Therefore, parasite therapy has been suggested; however, this treatment has potentially harmful effects.

Exosomes are 30--150 nm small membrane vesicles that are released into the extracellular medium by most cells ([@B40]; [@B6]). They mediate the transfer of proteins, genes (RNA, miRNA, and DNA) and lipids both *in vitro* and *in vivo*, and they function as a mode of intercellular communication ([@B6]). Previous studies have demonstrated that exosomes are involved in immunoregulation mechanisms including modulating antigen presentation, immune activation, immune suppression, and immune surveillance ([@B14]). Because exosomes have less cytotoxicity and biohazardous potential, and because the proteins and nucleic acids that they carry are not easily degraded, interest in the clinical applications of exosomes for therapy has grown; in fact, they exhibit more advantages than parental cells ([@B26]). Such as, dendritic cell (DC)-derived exosomes modulate the immune response and prevent the development of autoimmune diseases ([@B46]; [@B48]; [@B14]).

Because *S. japonicum* eggs have modulatory effects on colitis mice, and DC-derived exosomes prevent the development of autoimmune diseases, we hypothesized that exosomes derived from DCs treated with *S. japonicum* soluble egg antigen (SEA; SEA-treated DC exosomes) would have utility in the treatment of IBD. In the current study, SEA-treated DC exosomes were isolated from the supernatant of a culture of SEA-treated immature bone marrow-derived DCs (BMDCs). We found that SEA-treated DC exosomes attenuated dextran sulfate sodium (DSS)-induced colitis.

Materials and Methods {#s1}
=====================

Animals and Ethics
------------------

Male BALB/c mice aged 6 weeks and weighing 18--20 g were purchased from the experimental animal center of Sun Yat-sen University. All animal experimental procedures were approved by the Sun Yat-sen University Committee for Animal Research and conformed to the Guide for the Care and Use of Laboratory Animals of the National Institute of Health in China.

DC Generation and Exosome Purification
--------------------------------------

Bone marrow-derived DCs were generated using methods described by [@B18] and [@B23]. Briefly, BALB/c mice tibiae were removed and left in 70% ethanol for 2--5 min for disinfection and then washed in PBS. Cells within the marrow were disintegrated by vigorous pipetting. Thereafter, cells were cultured in medium RPMI-1640 (GIBCO, Germany) supplemented with Penicillin (100 U/ml, Sigma, Germany), Streptomycin (100 μg/ml, Sigma, Germany), [L]{.smallcaps}-glutamin (2 mM, Sigma, Germany), 10% heat-inactivated fetal calf serum (GIBCO, Germany), recombinant murine granulocyte--macrophage colony-stimulating factor (200 U/ml, perprotech, United States), recombinant murine interleukin-4 (5 ng/ml, perprotech, United States). At days 3, 5, 7 and 9, half of the cells culture supernatant was collected and centrifuged, the cell pellet resuspended and given back to the original plate, and then adding the equivalent of the medium. At day 10, cells can be used (BMDCs). The prepared BMDCs were treated with SEA (40 μg/ml) or untreated; after incubation for 24 h, the culture supernatant was harvested. Exosomes were purified from the supernatant using an exosome extraction kit (Invitrogen, United States) according to manufacturer's instructions.

Electron Microscopy and NanoSight
---------------------------------

Negative-staining transmission electron microscopy (TEM) was conducted to analyze the exosomes. Exosomes suspended in 2% glutaraldehyde were loaded on a copper grid and negatively stained with 3% (w/v) aqueous phosphotungstic acid for 1 min. The grid was then examined using an FEI Tecnai G2 Sprit Twin transmission electron microscope.DC exosome particles were analyzed using NanoSight NS300 (Malvern Instruments, United Kingdom).

Western Blotting
----------------

Dendritic cell exosomes were lysed in a western blotting lysis buffer, separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and subsequently electrotransferred onto a nitrocellulose blotting membrane (GE Healthcare Life Science, United Kingdom). The membranes were incubated with anti-mouse CD63, CD9, CD81 (BD Biosciences, United States) and Calnexin (Abcam, United Kingdom) antibodies and horseradish peroxidase (HRP) conjugated anti-mouse IgG (Jackson, United States), followed by chemiluminescent detection (Amersham, United States).

Induction of Colitis and Treatment
----------------------------------

Acute colitis was induced via the administration of DSS (molecular mass 36--50 kDa; MP Biomedicals, Illkirch, France) in drinking water (5.0%, wt/vol). The control group received regular drinking water. Treatments with exosomes or SEA were conducted via intraperitoneal (i.p.) injection (50 μg per mouse) from day 0 to day 6. Control groups received the same volume of vehicle (PBS). There were five mice in each group, and each group was used for three independent experiments.

Clinical Scoring of Disease
---------------------------

Mice were weighed daily, and the occurrence of diarrhea and bleeding were recorded. Scores were evaluated based on weight loss, stool type, and bleeding (**Table [1](#T1){ref-type="table"}**) as described by [@B36]. Briefly, weight loss was scored as 0 (\< 2%), 1 (≥ 2%-- \< 5%), 2 (≥ 5%-- \< 10%), 3 (≥ 10%-- \< 15%) or 4 (≥ 15%); stool was scored as 0 (normal), 1 (softer stool), 2 (moderate diarrhea), or 3 (diarrhea); and bleeding was scored as 0 (no rectal bleeding), 1 (weak hemoccult), 2 (blood in stool), or 3 (fresh rectal bleeding). The summed scores for weight loss, diarrhea, and bleeding were used as the clinical disease score \[disease activity index (DAI)\]. All scores were assessed by an independent observer blinded to the treatment.

###### 

Assessment of the DAI.

  Body weight loss (%)   Stool type          Bleeding                Score
  ---------------------- ------------------- ----------------------- -------
  \<2%                   Normal              No rectal bleeding      0
  ≥2--\<5%               Softer stool        Weak hemoccult          1
  ≥5--\<10%              Moderate diarrhea   Visual blood in stool   2
  ≥10--\<15%             Diarrhea            Fresh rectal bleeding   3
  ≥15%                   --                  --                      4
                                                                     

Macroscopic Assessment and Histologic Analysis
----------------------------------------------

On day 6, the animals were sacrificed, and their colons were removed. Colon length was measured as an indirect marker of inflammation. An independent observer who was blinded to treatment status determined the macroscopic characteristics. Briefly, the macroscopic scores were 0 (no damage), 1 (hyperemia without ulcers), 2 (hyperemia and wall thickening without ulcers), 3 (one ulceration site without wall thickening), 4 (two or more ulceration sites), 5 (0.5-cm extension of inflammation or major damage), and 6--10 (1-cm extension of inflammation or severe damage; **Table [2](#T2){ref-type="table"}**; [@B47]).

###### 

Assessment of macroscopic scores.

  Colon damage                                    Score
  ----------------------------------------------- -------
  No damage                                       0
  Hyperemia without ulcers                        1
  Hyperemia and wall thickening without ulcers    2
  One ulceration site without wall thickening     3
  Two or more ulceration sites                    4
  0.5 cm extent of inflammation or major damage   5
  1 cm extent of inflammation or severe damage    6--10
                                                  

Colons were fixed overnight in 4% (w/v) paraformaldehyde. Five-millimeter paraffin sections were stained with hematoxylin and eosin (H&E). The histopathological score was examined in a blinded fashion according to the criteria described by [@B36]. The following parameters were evaluated: extent of inflammation, infiltration of neutrophils and lympho-histiocytes, extent of crypt damage, crypt abscess, sub-mucosal edema, loss of goblet cells, and reactive epithelial hyperplasia (**Table [3](#T3){ref-type="table"}**). The aggregated individual histopathological scores were calculated.

###### 

Assessment of histopathological scores.

  Grade   Extent of inflammation           Infiltration neutrophils+ lympho-histiocytes   Extent of crypt damage    Crypt abscesses   Sub-mucosal edema   Loss of goblet cells   Reactive epithelial hyperplasia
  ------- -------------------------------- ---------------------------------------------- ------------------------- ----------------- ------------------- ---------------------- ---------------------------------
  0       None                             None                                           None                      None              None                None                   None
  1       Mucosa                           Focal                                          Basal one third           Focal             Focal               Focal                  Focal
  2       Mucosa+ submucosa                Multifocal                                     Basal two thirds          Multifocal        Multifocal          Multifocal             Multifocal
  3       Mucosa+submucosa+ muscle layer   Diffuse                                        Entire crypt damage                         Diffuse             Diffuse                Diffuse
  4       Transmura                                                                       Crypt damage+ulceration                                                                
                                                                                                                                                                                 

RNA Extraction and Real-Time PCR
--------------------------------

RNA was extracted was by Trizol reagent (Invitrogen, United States), according to the manufacturer's instructions. Total RNA (1000 ng) was converted to cDNA by a Thermo Scientific RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, United States). PCR reactions were performed using SYBR Green QPCR Master Mix (TaKaRa, Japan), according to manufacturer's instructions. The reaction over 40 cycles with denaturation at 95°C for 30 s followed by 95°C for 5 s and 60°C for 20 s. The primers of tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-17 (IL-17A), interleukin-12 (IL-12), interleukin-22 (IL-22) and transforming growth factor (TGF)-β are listed in **Table [4](#T4){ref-type="table"}**.

###### 

Primers used for real-time PCR analysis.

  Genes    Primer           sequence (5′→3′)
  -------- ---------------- -------------------------
  TNF-α    Forward primer   CCCTCACACTCAGATCATCTTCT
           Reverse primer   GCTACGACGTGGGCTACAG
  IFN-γ    Forward primer   GGAACTGGCAAAAGGATGGTGAC
           Reverse primer   GCTGGACCTGTGGGTTGTTGAC
  IL-12    Forward primer   TTGAGTGCCAATTCGATGAT
           Reverse primer   TTGAGGGCTTGTTGAGATGA
  IL-17A   Forward primer   GCTCCAGAAGGCCCTCAGACT
           Reverse primer   CCAGCTTTCCCTCCGCATTGA
  IL-22    Forward primer   TCAGTGCTAAGGATCAGTGCT
           Reverse primer   TGATTGCTGAGTTTGGTCAGG
  TGF-β    Forward primer   AACTATTGCTTCAGCTCCACAG
           Reverse primer   AGTTGGCATGGTAGCCCTTG
  GAPDH    Forward primer   ACTCCACTCACGGCAAATTC
           Reverse primer   TCTCCATGGTGGTGAAGACA
                            

Statistical Analyses
--------------------

Data were expressed as means ± SEM. Multiple groups were compared using a one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison *post hoc* test to determine statistical significance. Statistical significance between two experimental groups was assessed using the Independent-Sample *t*-test. A value of *P \<* 0.05 was considered as significant.

Results
=======

Extraction and Identification of SEA-Treated and Untreated DC Exosomes
----------------------------------------------------------------------

Bone marrow-derived DCs were cultured *in vitro* and either treated with SEA or left untreated. Culture supernatants were collected after 24 h. Exosomes were isolated from supernatants using exosome extraction kits according to the manufacturer's instructions. To verify the purity and quality of the exosomes, negative-staining TEM was conducted to evaluate exosome morphology. Negative-staining TEM revealed that most untreated DC exosomes and SEA-treated DC exosomes displayed closed round vesicles with diameters of 30--150 nm (**Figure [1A](#F1){ref-type="fig"}**), indicating that the exosomes were undamaged during purification and uncontaminated with microparticles of cellular organelles or membranes. Furthermore, to test the expression of the exosome-specific markers, CD63, CD9, and CD81 were confirmed via western blotting; these markers were expressed at high levels (**Figure [1B](#F1){ref-type="fig"}**). Calnexin, the negative marker of exosomes also be determined by western blotting to test the purity of exosomes (**Figure [1B](#F1){ref-type="fig"}**). In addition, the size distribution profile of the exosomes was investigated using NanoSight, which revealed a size peak of 108 nm among untreated DC exosomes and 104 nm among SEA-treated DC exosomes (**Figure [1C](#F1){ref-type="fig"}**). These results indicate the successful isolation of the exosomes from the culture supernatants.

![Successful isolation of exosomes from the supernatant of DCs treated with SEA (SEA-EXO) or untreated (EXO). **(A)** Exosome ultrastructure was confirmed via negative-staining TEM. **(B)** The expressions of the exosome-specific markers CD63, CD9, and CD81 were confirmed via western blotting. **(C)** The size distribution profile of the exosomes was investigated using NanoSight.](fphar-08-00651-g001){#F1}

SEA-Treated DC Exosomes Alleviate Clinical Scores of Acute DSS-Induced Colitis Mice
-----------------------------------------------------------------------------------

To test whether SEA-treated DC exosomes attenuated colitis, acute DSS-induced colitis mice were injected i.p. with SEA-treated DC exosomes (50 μg/mouse) from day 0 to day 6. Clinical scoring was based on weight loss, diarrhea, and bleeding and expressed as the DAI. DSS treatment induced substantial weight loss in mice. After DSS administration, the mice of the DSS+PBS group lost weight over time, with a maximum body weight loss of 26.75% within 6 days (**Figure [2A](#F2){ref-type="fig"}**). Compared with the DSS+PBS group, weight loss in the colitis mice treated with SEA-treated DC exosomes was significantly alleviated (14.31% vs. 26.75% on day 6; *P* \< 0.05). In addition, compared with untreated DC exosomes and SEA, SEA-treated DC exosomes better alleviated body weight loss (**Table [5](#T5){ref-type="table"}**). Second, DSS treatment caused severe diarrhea and bleeding that persisted until the sacrifice of the colitis mice. Untreated DC exosomes, SEA-treated DC exosomes and SEA alleviated the severity of diarrhea and bleeding; however, the effect of SEA-treated DC exosomes was greater than that of DC exosomes and SEA. The DAI (the sum of the weight loss, diarrhea and bleeding scores) of the colitis mice treated with SEA-treated DC exosomes was lower than that of the colitis mice treated with PBS, SEA-untreated DC exosomes and SEA (**Figure [2B](#F2){ref-type="fig"}** and **Table [5](#T5){ref-type="table"}**). These results suggest that SEA-treated DC exosomes attenuate clinical scores in DSS-induced colitis mice, and this effect was greater than that of SEA-untreated DC exosomes and SEA.

![Clinical scores of acute DSS-induced colitis mice treated with exosomes. **(A)** The effect of exosomes on the body weight of mice (50 μg/mouse). Mice were weighed daily. **(B)** The effect of exosomes on the DAI. The DAI was evaluated using the parameters of weight loss, diarrhea, and bleeding. Statistical analyses were performed using a one-way ANOVA followed by Dunnett's multiple comparison *post hoc* test (^∗^*P* \< 0.05, DSS+SEA-EXO versus DSS+PBS).](fphar-08-00651-g002){#F2}

###### 

Values of the evaluation indexes.

                Body weight loss on day 6 (mean)   DAI (mean)   Colon length (mean)   Macroscopic scores (mean)   Histopathological score (mean)   n (Three independent experiments)
  ------------- ---------------------------------- ------------ --------------------- --------------------------- -------------------------------- -----------------------------------
  Water+PBS     0.00%                              0.00         10.13 cm              0.00                        0                                5
  DSS+PBS       27.75%                             10.00        5.47 cm               8.33                        17                               5
  DSS+SEA       21.79%                             7.67         7.07 cm               4.67                        9.67                             5
  DSS+EXO       19.00%                             7.00         6.30 cm               4.66                        12.33                            5
  DSS+SEA-EXO   14.31%                             5.33         8.20 cm               3.33                        7.33                             5
                                                                                                                                                   

SEA-Treated DC Exosomes Ameliorate Reduction in Colon Length and Macroscopic Scores in Acute DSS-Induced Colitis Mice
---------------------------------------------------------------------------------------------------------------------

Dextran sulfate sodium significantly reduces colon length in colitis mice. Therefore, the therapeutic potential of SEA-treated DC exosomes in suppressing acute colitis was investigated using colon length. The results showed that compared with the colitis mice treated with PBS, the colons of the colitis mice treated with SEA-treated DC exosomes were longer (8.2 ± 1.3 cm vs. 5.5 ± 1 cm, *P* \< 0.01; **Figures [3A,B](#F3){ref-type="fig"}**). In addition, the colons of colitis mice treated with SEA-treated DC exosomes were longer than those in mice treated with SEA-untreated DC exosomes and SEA (**Figures [3A,B](#F3){ref-type="fig"}** and **Table [5](#T5){ref-type="table"}**). Mean colon macroscopic scores were assessed based on hyperemia, wall thickening, ulceration, inflammation extension, and damage. Compared with the DSS+PBS group, the mean colon macroscopic scores of colitis mice treated with SEA-treated DC exosomes were significantly suppressed (**Figure [3C](#F3){ref-type="fig"}** and **Table [5](#T5){ref-type="table"}**). In addition, the mean colon macroscopic scores of colitis mice treated with SEA-treated DC exosomes were lower than those of colitis mice treated with SEA-untreated DC exosomes and SEA (**Figure [3C](#F3){ref-type="fig"}** and **Table [5](#T5){ref-type="table"}**). These data demonstrate that SEA-treated DC exosomes ameliorate reduction in colon length and macroscopic scores in acute DSS-induced colitis mice more effectively than DC exosomes untreated with SEA and SEA.

![Colon length and colon macroscopic scores in acute DSS-induced colitis mice treated with exosomes. **(A)** On day 6, the mice were sacrificed, and their colons were removed. Colon length was measured as an indirect marker of inflammation. **(B)** The macroscopic appearance of colons. Mean colon length and typical injury findings are presented. **(C)** Mean macroscopic scores of colons. Statistical analyses of multiple groups were performed using a one-way ANOVA followed by Dunnett's multiple comparison *post hoc* test versus DSS+PBS (^∗^*P \<* 0.05, ^∗∗^*P \<* 0.01, ^∗∗∗^*P \<* 0.001). Statistical significance between two experimental groups was assessed using the Independent-Sample *t*-test (^&^*P* \< 0.05, ^&&^*P* \< 0.01).](fphar-08-00651-g003){#F3}

SEA-Treated DC Exosomes Prevent Colon Damage in Acute DSS-Induced Colitis Mice
------------------------------------------------------------------------------

Finally, damage was assessed via a histologic examination. Colonic sections revealed the complete disruption of the colonic architecture in colitis mice. Colitis mice treated with SEA-treated DC exosomes retained intact colonic architecture, including reduced numbers of mucosal erosions, smaller ulcerations, lower hyperplasia, and decreased inflammatory infiltration. The damage severity in mice treated with SEA-untreated DC exosomes and SEA were greater than that in mice treated with SEA-treated DC exosomes (**Figure [4A](#F4){ref-type="fig"}**). Consistent with the histologic examination, the histological scores of colitis mice treated with SEA-treated DC exosomes were significantly lower than PBS-treated mice, SEA-untreated DC exosomes treated mice and SEA-treated mice (**Figure [4B](#F4){ref-type="fig"}** and **Table [5](#T5){ref-type="table"}**). Taken together, these results indicate that SEA-treated DC exosomes prevent colon damage in acute DSS-induced colitis mice, and this effect was greater than that achieved with SEA-untreated DC exosomes and SEA.

![Histopathological changes in the colons of acute DSS-induced colitis mice treated with exosomes. **(A)** Colon tissue samples were examined using H&E staining (5×, 10×, 20×, and 40×). **(B)** Histopathological scores of colon tissue samples. Statistical analyses of multiple groups were performed using a one-way ANOVA followed by Dunnett's multiple comparison *post hoc* test versus DSS+PBS (^∗∗^*P \<* 0.01, ^∗∗∗^*P \<* 0.001). Statistical significance between two experimental groups was assessed using the Independent-Sample *t*-test (^&^*P \<* 0.05).](fphar-08-00651-g004){#F4}

SEA-Treated DC Exosomes Regulate Inflammatory Cytokines Production in Acute DSS-Induced Colitis Mice
----------------------------------------------------------------------------------------------------

Inflammatory cytokines, such as TNF- α, IFN-γ, IL-17A, IL-12, IL-22 and TGF-β, play important roles in the pathogenesis of IBD. To determine whether SEA-treated DC exosomes can regulate the inflammatory cytokines production in colitis mice colon, the expression levels of inflammatory cytokines were examined by Real-time PCR. The results demonstrated that proinflammatory cytokines TNF- α, IFN-γ, IL-17A, IL-12, IL-22 were high expression levels in the DSS+PBS group (**Figure [5](#F5){ref-type="fig"}**). Compared with DSS+PBS group, TNF- α, IFN-γ, IL-17A, IL-12, IL-22 were reduced by treatment with SEA-treated DC exosomes (**Figure [5](#F5){ref-type="fig"}**). Furthermore, the expression levels of TNF- α, IFN-γ, IL-17A, IL-12, IL-22 in DSS+SEA-EXO group were lower than DSS+SEA group and DSS+EXO group (**Figure [5](#F5){ref-type="fig"}**). In addition, the expression levels of anti-inflammatory cytokines TGF-β in DSS+SEA-EXO group was higher than other groups (**Figure [5](#F5){ref-type="fig"}**). These results indicate that SEA-treated DC exosomes regulate inflammatory cytokines production in acute DSS-induced colitis mice.

![Pro-inflammatory cytokine and immunoregulatory cytokine expression in the colons of acute DSS-induced colitis were determined by Real-time PCR. The mRNA expression levels of TNF- α, IFN-γ, IL-17A, IL-12, IL-22, and TGF-β were detected by Real-time PCR, the housekeeping gene GAPDH was used as internal reference. Statistical analyses of multiple groups were performed using a one-way ANOVA followed by Dunnett's multiple comparison *post hoc* test versus DSS+PBS (^∗^*P \<* 0.05, ^∗∗^*P \<* 0.01). Statistical significance between two experimental groups was assessed using the Independent-Sample *t*-test (^&^*P \<* 0.05, ^&&^*P \<* 0.01).](fphar-08-00651-g005){#F5}

Discussion
==========

Crohn's disease and UC are the two major clinicopathological subtypes of IBD with chronic and remittent-relapsing intestinal inflammation and unclear etiology ([@B3]). The major factors likely responsible for IBD are environmental, genetic and immunoregulatory ([@B10]). Traditional treatment of IBD primarily uses 5-ASA agents, steroids, antimicrobials, and select immunomodulators ([@B2]). However, these drugs have limitations and adverse effects. Over the past two decades, IBD treatment via biologic therapies has demonstrated high efficacy and an excellent safety profile ([@B9]; [@B5]).

Exosomes are small (30--150 nm) extracellular vesicles secreted by many cells that function as key mediators and communicators between cells and transport and deliver proteins, lipids, and nucleic acids ([@B20]). In addition, exosomes play an important role in pathophysiological processes including immune responses and inflammation, tumor growth, and infection ([@B1]). Therefore, exosomes have potential clinical applications in diagnosis, prognosis, and treatment. Evidence showed that exosomes took part in maintenance of homeostasis in intestinal mucosal immunity, including inducing oral tolerance to antigens and promoting epithelial barrier function ([@B43]). Exosomes derived from bone marrow mesenchymal stem cells can protect against TNBS-induced colitis by modulating of inflammation, suppressing oxidative stress and attenuating apoptosis ([@B44]). Exosomes released by granulocytic myeloid-derived suppressor cells attenuate DSS-induced colitis by promoting Tregs expansion and inhibiting Th1 cells proliferation ([@B41]). Furthermore, study showed that exosomes from human umbilical cord mesenchymal stem cells have effects on alleviating DSS-induced colitis through modulating IL-7 expression in macrophages ([@B25]). DCs, as the most potent professional antigen-presenting cell in the immune system, play a key role in immune responses through direct contact with other cell types and the secretion of cytokines ([@B33]). DC-derived exosomes are nanometer-sized membrane vesicles secreted by DCs. Their molecular composition includes the surface expression of costimulatory molecules, functional MHC-peptide complexes and other immune function-associated molecules ([@B31]). Previous work has shown that DC-derived exosomes can induce antitumor immunity in animal models and human clinical trials; exosomes have distinct advantages over cell-based immunotherapies involving DCs ([@B16]; [@B31]).

Epidemiologic studies support the hypothesis that helminth parasites show great therapeutic potential for treating inflammatory diseases including IBD ([@B27]). The protective and therapeutic effects of helminth parasite infection are corroborated by animal experiments and clinical trials. For instance, *Hymenolepis diminuta, Heligmosomoides polygyrus*, and *Trichinella spiralis* alleviate dinitrobenzene sulfonic acid-induced colitis in mice ([@B37]; [@B19]; [@B11]), *Echinococcus granulosus* has anti-inflammatory effects and protects the integrity of the intestinal mucosa in mice with DSS-induced colitis ([@B30]), and *Ancylostoma ceylanicum* and *A. caninum* ameliorate pathology in DSS-induced colitis mice via the down-regulation of Th1 and Th17 responses ([@B7]; [@B39]). In addition, *S. japonicum* and *S. mansoni* eggs showed modulatory effects in a mouse model of colitis ([@B45]; [@B42]; [@B17]).

Given that DC-derived exosomes prevent the development of autoimmune diseases and that *S. japonicum* eggs have modulatory effects on colitis in mice, we were interested in determining whether SEA-treated DC exosomes have potential uses in the treatment of IBD. The present study extracted exosomes from DC culture supernatants treated or untreated with SEA. Exosomes were identified via negative-staining TEM, NanoSight and western blotting. Exosomes displayed closed round vesicles with diameters of 30--150 nm and expressed high levels of CD63, CD9, CD81 (**Figure [1](#F1){ref-type="fig"}**). We subsequently treated DSS-induced colitis mice with SEA-treated DC exosomes; the results indicated that body weight loss and the DAI decreased significantly after treatment with SEA-treated DC exosomes (**Figure [2](#F2){ref-type="fig"}**). Moreover, after treatment with SEA-treated DC exosomes, the colon lengths of colitis mice improved, and their mean colon macroscopic scores decreased (**Figure [3](#F3){ref-type="fig"}**). Histologic examinations and histological scores showed that SEA-treated DC exosomes prevented colon damage in acute DSS-induced colitis mice (**Figure [4](#F4){ref-type="fig"}**). In addition, SEA-treated DC exosomes can regulate inflammatory cytokines production in acute DSS-induced colitis mice (**Figure [5](#F5){ref-type="fig"}**). These results indicate that SEA-treated DC exosomes attenuate the severity of acute DSS-induced colitis mice, and this effect is greater than that achieved using DC exosomes untreated with SEA and SEA. In conclusion, our work suggests that SEA-treated DC exosomes may be useful as a new approach to treat IBD.
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